CureDiab at the International Conference on Fatty Liver (ICFL) 2022

16. Mai 2022

Our company was delighted to be at ICFL 2022 to show the potential of positive allosteric modulation of the GABAA receptor in an oral presentation. This exciting congress reflected the economic impact of diagnostic and therapeutic gaps, which gave us the chance for intense discussion with international experts of NAFLD and to expand our network. We know we have an uphill battle but confident we’ll get there!